collegiumpharma.com - COLL Net Assets per Single Share

Public company logo of collegiumpharma.com (COLL)

Collegium Pharmaceutical (COLL) serves as a trusted developer of overdose-resistant analgesics, a quality highly valued by pain management specialists. The company has outsourced its manufacturing processes to third-party contractors while maintaining strict quality oversight. The business relies on complex patents and rigorous FDA and DEA controls, and the current metric stands at 9.62. This price chart for Collegium Pharmaceutical (COLL) shares reflects the price action of this pharmaceutical player.

Collegium Pharma (COLL) Equity per Share: for the period 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for collegiumpharma.com (COLL)

- price and consensus price forecast:
Price Chart Collegium Pharmaceutical Inc|COLL - Price Target Chart
- market capitalization data:
Market Value Collegium Pharmaceutical, Inc.|COLL - Total Company Value
- book capitalization data:
Net Assets per Single Share Collegium Pharmaceutical|COLL - Accounting Capitalization|Market Capitalization to Book Value Ratio collegiumpharma.com|COLL - Company Total Assets
- debt and liquidity data:
Debt to Equity Collegium Pharmaceutical|COLL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Collegium Pharmaceutical, Inc.|COLL - Company Total Debt|Debt to Book Capitalization Ratio Collegium Pharmaceutical, Inc.
Fundamental company valuation:Collegium Pharmaceutical Inc, COLL
Signature product of collegiumpharma.com

Book value per share reflects the portion of equity attributable to a single common share. Growth in this metric indicates the accumulation of net assets and the financial stability of the business. By analyzing the equity per common share chart, an investor assesses the protection of their investment. For Collegium Pharmaceutical (COLL), this metric is critical due to potential payouts from lawsuits. The stability of the curve will help determine whether the capital offsets the risks associated with the opioid crisis.

Competitor analysis

INDV - Net Assets per Single Share|CRON: Net Assets per Single Share|Canopy Growth (CGC) - Net Assets per Single Share|HITI (hightideinc.com) - Net Assets per Single Share|Net Assets per Single Share Aurora Cannabis, Inc. (ACB)|Equity per Share Achieve Life Sciences Inc.|Book Value per Share SKYE|Book Value per Share ANEB (Anebulo Pharma)|Net Assets per Single Share InterCure|Accounting Value of a Share Nutriband Inc NTRB|NSRX: Book Value per Share|IGC: Accounting Value per Share|Net Assets per Single Share MIRA|Net Asset Value per Share Flora Growth Inc|IMCC - Accounting Value per Share|Accounting Value of a Share Adial|ARTL - Book Value per Share|Share Book Value ensysce.com (ENSC)|Book Value per Share TTNP (Titan Pharmaceuticals, Inc.)|Greenlane Corp - Book Value per Share|Net Assets per Single Share InMed Pharmaceuticals (INM)|AKAN: Accounting Value of a Share|ENVB (Enveric Biosciences, Inc.) - Net Assets per Single Share|Bright Green Corporation (BGXX) - Accounting Value per Share|Book Value per Share HPCO